United Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/18/2024
United Therapeutics Stock Forecast and Price Target
United Therapeutics's stock is projected to advance by 26.22% from the previous closing price if it reaches the average target of $297.00 by the year's end, as three reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $375.00 and a low-end estimate of $183.00. If you're looking for information on United Therapeutics stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.
26.22% Upside
United Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, United Therapeutics's Price has decreased from $153.28 to $0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will jump to $228.85 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$144.77 | Buy/Sell | $174.55 | 17.43% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.42 | Buy/Sell | $32.87 | 19.98% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$264.07 | Buy/Sell | $303.65 | 20.14% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$393.10 | Buy/Sell | $457.59 | 14.47% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$901.19 | Buy/Sell | $961.26 | 16.51% |
United Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, United Therapeutics's Revenue has grown, moving from $1.48B to $2.33B – an increase of 56.91%. In the next year, analysts predict that Revenue will jump to $2.50B – up 7.63% from the current level. Looking ahead to seven years, experts forecast that Revenue will grow by 81.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$66.93 | Buy/Sell | $87.82 | 22.53% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£15.90 | Buy/Sell | £17.30 | 22.64% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$192.16 | Buy/Sell | $299.62 | 51.96% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.25€ | Buy/Sell | 45.15€ | 21.90% |
| CE Stock Forecast | Celanese | Hold |
13
|
$154.49 | Buy/Sell | $148.23 | 3.57% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.10 | Buy/Sell | $11.73 | 8.11% |
United Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for United Therapeutics has grown by 93.35%, going from $640.90M to $1.24B. According to the 5 analysts polled, in the next year, United Therapeutics's EBITDA will fall by 0.44%, reaching $1.23B. By 2030, professionals believe that United Therapeutics's EBITDA will have decreased by 12.20%, falling to $1.09B.
United Therapeutics EBIT Forecast for 2023 - 2025 - 2030
United Therapeutics's EBIT has grown in the last three years, jumping from $591.00M to $1.19B – an increase of 100.68%. In the next year, analysts predict that EBIT will reach $1.29B – an increase of 8.83%. For the next seven years, the forecast is for EBIT to grow by 106.07%.
United Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, United Therapeutics's EPS has decreased from $14.46 to $0.00 – a 100.00% drop. In the next year, analysts predict that EPS will jump to $21.59 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
.jpg)